Data for this study come from sources detailed in the paper. Data on CVD risk factors come from the CESCAS I study (<https://estudiocescas.iecs.org.ar/>), the 2013 National Risk Factor Survey (<http://www.msal.gob.ar/ent/index.php/vigilancia/publicaciones/encuestas-poblacionales>), and the PrEViSTA study (<https://www.ncbi.nlm.nih.gov/pubmed/24024917>). Framingham Heart Study data are available following approval of research applications submitted through the National Heart, Lung, and Blood Institute\'s Biologic Specimen and Data Repository Information Coordinating Center (available at <http://biolincc.nhlbi.nih.gov/studies/framcohort/?q=framingham> for the Framingham Cohort and <http://biolincc.nhlbi.nih.gov/studies/framoffspring/?q=framingham> for the Offspring study). Data on sugar sweetened beverage consumption come from CESCAS I study (<https://estudiocescas.iecs.org.ar/>), the 2005 National Nutrition and Health Survey (<http://www.msal.gob.ar/images/stories/bes/graficos/0000000257cnt-a08-ennys-documento-de-resultados-2007.pdf>), and Euromonitor (<https://www.euromonitor.com/argentina>). Vital statistics and census data are publicly available from government sources described in the paper.

Introduction {#sec007}
============

As one of the main sources of added sugar in Western diets, sugar-sweetened beverage (SSB) consumption is suggestive of poor dietary quality \[[@pmed.1003224.ref001]\] and is associated with obesity, type 2 diabetes mellitus (from now on, referred to only as "diabetes"), and hypertension \[[@pmed.1003224.ref002]--[@pmed.1003224.ref008]\]. While sales of sweet soft drinks in North America leveled off after 2012, in Latin America they doubled in the period 2000--2013 \[[@pmed.1003224.ref009]\]. Increased SSB consumption during this time period was strongly correlated with growing rates of overweight and obesity in the region \[[@pmed.1003224.ref009]\].

Argentina is one of the world's highest consumers of SSBs, with consumption estimates of 120 to 130 liters of SSB per capita per year \[[@pmed.1003224.ref010],[@pmed.1003224.ref011]\]. Between 2005 and 2013, the combined overweight and obesity prevalence in Argentina rose from 49% to 58%; 21% of the population presented obesity in 2013 \[[@pmed.1003224.ref012]\]. This increase in obesity has contributed to rising rates of diabetes---diagnosed in 9.8% of Argentines in 2013 \[[@pmed.1003224.ref012]\]---and to Argentina's very high rates of cardiovascular disease (CVD) \[[@pmed.1003224.ref009]\]. Given that relatively small increases in weight heighten the risk of diabetes and CVD \[[@pmed.1003224.ref013]--[@pmed.1003224.ref016]\], SSBs may contribute to disease development even among individuals without obesity.

Due to the increase in obesity prevalence and its related illnesses, reducing SSB consumption---which in Argentina consists overwhelmingly of sugary sodas \[[@pmed.1003224.ref010]\]---is a public health priority. The World Health Organization has suggested SSB taxation as a fiscal policy intervention for the prevention of noncommunicable diseases \[[@pmed.1003224.ref017]\]. The success of Mexico's SSB tax, which led to an 11% price increase followed by a 7.3% reduction in SSB sales within the first 2 years, has placed SSB taxes on the menu of policy options for all Latin American countries \[[@pmed.1003224.ref018]\].

In order to provide local policy makers estimates of the projected impact of SSB taxation on the health of the Argentine population, we used a well-established computer simulation model, the Cardiovascular Disease Policy Model (CVD Policy Model), adapted for the Argentine population, to simulate the impact of reduced SSB consumption on national diabetes incidence, cardiovascular events, and mortality.

Methods {#sec008}
=======

CVD Policy Model-Argentina {#sec009}
--------------------------

The CVD Policy Model is a computer simulation, state transition (Markov) model that estimates the prevalence and incidence of CVD by using demographic, epidemiological, vital statistic, and hospital data measured in the population 35 years old and older. The model separates the population into those without and with CVD. Those without CVD are stratified into cells defined by sex, age decile, and levels of the following cardiovascular risk factors: systolic blood pressure (SBP; \<130; 130--139.9; ≥140 mmHg), low-density lipoprotein cholesterol (\<100; 100--129.9; ≥130 mg/dl), high-density lipoprotein cholesterol (\<40; 40--59.9; ≥60 mg/dl), smoking status (no exposure, second-hand smoke exposure, active smoking), type 2 diabetes status (yes versus no), and body mass index (BMI) (\<25; 25--29.9; ≥30 kg/m^2^). In annual cycles, those without preexisting CVD have probabilities of experiencing incident coronary heart disease (CHD), incident stroke, or death from non-cardiovascular causes, with transition rates dependent on age, sex, and risk factor values. The population with prior CVD has annual rates of recurrent cardiovascular events or death from cardiovascular or non-cardiovascular causes, with transition rates dependent on age, sex, and prior CVD status. Each annual cycle, new 35-year-olds enter the simulated population, measured from census projections \[[@pmed.1003224.ref019],[@pmed.1003224.ref020]\], and those who die or reach 95 years of age exit the simulated population.

The first version of the CVD Policy Model-Argentina was developed in 2009 \[[@pmed.1003224.ref021]\]. Since then, new sources of information have become available and have replaced original inputs, including the 2010 National Census \[[@pmed.1003224.ref022]--[@pmed.1003224.ref024]\], the 2013 National Risk Factor Survey \[[@pmed.1003224.ref012]\], the Study for the Detection and Follow-up of Cardiovascular Disease Risk Factors in the Southern Cone of Latin America (CESCAS I study) \[[@pmed.1003224.ref025]\], and the Program for the Epidemiological Evaluation of Stroke in Tandil (PrEViSTA) \[[@pmed.1003224.ref026]\]. The updated version of the model was calibrated with an accuracy of 99.5% when comparing CVD events and deaths predicted by this model and those observed in national data for 2010 \[[@pmed.1003224.ref027]\]. A more detailed explanation of model development and update can be found in the [S1 Appendix](#pmed.1003224.s001){ref-type="supplementary-material"}, as well as in a previous publication \[[@pmed.1003224.ref027]\].

The study's prospective protocol can be found in the [S1 Protocol](#pmed.1003224.s004){ref-type="supplementary-material"}. This study is reported as per the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline ([S1 STROBE Checklist](#pmed.1003224.s005){ref-type="supplementary-material"}).

Estimating daily SSB consumption in Argentina {#sec010}
---------------------------------------------

To model the impact of a decrease in SSB consumption on cardiovascular health, we first estimated per capita daily consumption of SSBs in Argentina by sex and age group. We focused specifically on sugar-sweetened soda consumption (hereafter labeled "SSB") and estimated mean daily 12-ounce servings of these beverages. This serving size is equivalent to a can of soda in Argentina. Due to a lack of a single source of nationally representative data on SSB consumption for each age and sex stratum modeled, we generated 2 sets of estimates (a "low" estimate and a "high" estimate) using the best available data and modeled both scenarios to represent the range of likely SSB intake in the population.

We obtained our "low" estimates from the CESCAS I study, an ongoing observational prospective cohort designed to study CVD prevalence and risk factors in Southern Latin America. In 2010--2011, CESCAS I measured self-reported average daily SSB consumption among 3,300 adults aged 35 to 74 years old in 2 Argentinean cities (Bariloche and Marcos Paz) \[[@pmed.1003224.ref025]\]. The questionnaire was based on the Spanish version of the Dietary History Questionnaire I, a self-administered food-frequency questionnaire developed for the Spanish-speaking population in the US \[[@pmed.1003224.ref028]\] and validated for use in Argentina \[[@pmed.1003224.ref029]\]. We assumed that consumption among people 75 years of age and older was equivalent to that reported by those 65 to 74 years old.

We derived a "high" estimate using the 2005 National Nutrition and Health Survey (Encuesta Nacional de Nutrición y Salud \[ENNyS\]) in combination with sales report data from Euromonitor measured in 2005 and 2015. The ENNyS, a survey conducted in 2005 among Argentine women 10 to 49 years old \[[@pmed.1003224.ref030]\], reported mean daily soda consumption. We applied that figure to women aged 35--44 years in the model. However, recognizing that daily soda consumption includes both regular and diet soda, we estimated the consumption of regular soda by using the fraction of regular soda (87.1%) that makes up sales of total soda (regular and diet) in the 2005 Euromonitor sales data \[[@pmed.1003224.ref010]\]. Finally, we compared Euromonitor overall sales data in 2015 to 2005 and corrected for the difference in population size between those years. By doing so, we derived a mean daily consumption of regular soda of 269.6 ml for women 35--44 years old in 2015. We then generated estimates of SSB intake for each age/gender group by scaling to the proportional intake observed for each group relative to 35- to 44-year-old women as measured in CESCAS I. A more detailed description of these calculations, as well as a comparison with CESCAS I reported consumption, can be seen in [S1 Appendix](#pmed.1003224.s001){ref-type="supplementary-material"}.

SSB effect on CVD risk factors {#sec011}
------------------------------

SSB consumption has been shown to have a direct effect on SBP and diabetes, as well as indirect effects on SBP and diabetes that are mediated through changes in BMI \[[@pmed.1003224.ref002]--[@pmed.1003224.ref004],[@pmed.1003224.ref008]\]. We modeled both direct and indirect effects of reductions in SSB consumption using inputs shown in [Table 1](#pmed.1003224.t001){ref-type="table"}. The model applies all changes in the first year of the simulation and then assumes that they are held constant.

10.1371/journal.pmed.1003224.t001

###### Effect of 12-ounce serving size of SSB on diabetes incidence, BMI, and SBP.

![](pmed.1003224.t001){#pmed.1003224.t001g}

  Variable                                                                                                                SSB consumption effect
  ----------------------------------------------------------------------------------------------------------------------- ----------------------------------------------
  SBP; SSB consumption independent effect                                                                                 Men: 0.78 mmHg (0.09--1.47)
  Women: 0.61 mmHg (0.27--1.48) \[[@pmed.1003224.ref031]\]                                                                
  Independent effect of 1 additional serving of SSB on risk of diabetes, RR (95% CI)                                      1.19 (1.09--1.31) \[[@pmed.1003224.ref032]\]
  SBP; SBP change per 1-unit increase in BMI[^a^](#t001fn001){ref-type="table-fn"}                                        Men: 1.43 mmHg (1.23--1.64)
  Women: 1.24 mmHg (1.09--1.39) \[[@pmed.1003224.ref033]\]                                                                
  Association between a 1-unit increase in BMI and incident diabetes, RR (95% CI)[^a^](#t001fn001){ref-type="table-fn"}   Decreases over age;
  1.17 (0.97--1.43) for 55--64 years old \[[@pmed.1003224.ref034]--[@pmed.1003224.ref038]\]                               
  BMI                                                                                                                     Calories from SSB translated to weight;
  3,500 calories = 1 pound \[[@pmed.1003224.ref039]\]                                                                     

^a^BMI-mediated changes in diabetes and SBP are expressed for each unit kg/m^2^ change in BMI.

**Abbreviations**: BMI, body mass index; RR, relative risk; SBP, systolic blood pressure; SSB, sugar-sweetened soda

We assumed that decreasing intake of SSB by one 12-ounce serving per day is associated with a reduction in SBP of 0.78 mmHg (95% CI 0.09--1.47) in men and 0.61 mmHg (95% CI 0.27--1.48) in women independent of SBP changes mediated through BMI \[[@pmed.1003224.ref031]\]; similarly, BMI-independent diabetes risk was assumed to decrease by a factor of 1.19 (95% CI 1.09--1.31) \[[@pmed.1003224.ref032]\].

Weight and height information for the Argentina population was obtained from the 2013 National Risk Factor Survey \[[@pmed.1003224.ref012]\], and changes in weight assumed for the interventions were converted into changes in kilograms per square meter of BMI. Each unit kilogram-per-square-meter decrease in BMI was assumed to result in a 1.43 mmHg and 1.24 mmHg decrease in SBP in men and women, respectively \[[@pmed.1003224.ref033]\]. The association between changes in BMI and changes in diabetes incidence was estimated using Framingham Heart Study data \[[@pmed.1003224.ref034]--[@pmed.1003224.ref038]\].

We assumed that changes in SSB consumption were associated with changes in weight using the conversion 3,500 kcal = 1 pound; one serving of soda contains 150 calories \[[@pmed.1003224.ref039]\]. Although imbalances between the intake and utilization rates of macronutrients will result in changes in body weight, the relationship between caloric consumption and weight loss/gain, as well as caloric compensation when reducing one source of calories, are not fully understood. Consequently, we decided to include 3 scenarios with different degrees of caloric compensation (and therefore different changes in BMI) after a decrease in SSB consumption: 100%, 39% (a reported average compensation rate), and 0% caloric compensation scenarios \[[@pmed.1003224.ref040],[@pmed.1003224.ref041]\]. Under assumptions of 100% calorie compensation (i.e., no change in BMI), the independent effect of SSB consumption on SBP and diabetes drives changes in CVD outcomes.

A more detailed description of our approach to modeling the relationship between changes in SSB consumption and CVD risk factors and outcomes was published in our previous work on SSB in the US and Mexico \[[@pmed.1003224.ref042],[@pmed.1003224.ref043]\].

Model simulations {#sec012}
-----------------

We modeled the impact of a reduction in SSB consumption on diabetes incidence, myocardial infarctions, strokes, CVD mortality, and all-cause mortality using the CVD Policy Model-Argentina over a 10-year period from 2015 to 2024.

A recent analysis estimated that the price elasticity of soda consumption in Argentina is very close to 1 (−1.12) \[[@pmed.1003224.ref044]\]. Therefore, we assumed that a 10% or 20% tax could translate into a 10% or 20% decrease in soda consumption (assuming that all, or nearly all, of the cost from the tax is passed on to the consumer) and compared the health impacts of each taxation scenario to the base case of no change in consumption. We also modeled a 40% reduction in SSBs which, though difficult to achieve at a population level, highlights the potential benefits of very high reduction in soda consumption. We applied each taxation scenario to both our "low" and "high" estimates of current SSB consumption in Argentina, and our main analyses assumed 39% calorie compensation \[[@pmed.1003224.ref041]\].

Probabilistic sensitivity analyses {#sec013}
----------------------------------

We used Monte Carlo simulations to generate 95% uncertainty intervals (UIs) around our primary outcome measures for each intervention scenario. The 95% confidence intervals for estimates of the effect of changes in SSB consumption on SBP and on diabetes risk as well as the beta inputs for model risk functions defining the relationship between risk factors and incident diabetes, incident CHD, incident stroke, and non-CVD death are included in Table C of [S1 Appendix](#pmed.1003224.s001){ref-type="supplementary-material"}. There were 1,000 random draws from a standard normal distribution, scaled to the mean and confidence interval, for each varied parameter. The Monte Carlo program, written in Python, generated a new set of input parameters drawn from the distributions for each iteration, ran the given iteration base case and reduced SSB consumption simulations with the new parameters, and stored the outcomes for each iteration. The 95% UIs for each outcome were then calculated using Microsoft Excel 2016.

Results {#sec014}
=======

Over the 2015--2024 period, a 10% reduction in SSB consumption with a caloric compensation of 39% is projected to reduce diabetes cases by between 13,300 (95% UI 10,800--15,600 \[low SSB consumption estimate\]) and 27,700 cases (95% UI 22,400--32,400 \[high SSB consumption estimate\]), i.e., 1.7% and 3.6% fewer cases, respectively, compared to a scenario of no change in SSB consumption. This same scenario leads to an estimated 2,500 (95% UI 2,200--2,800) to 5,100 (95% UI 4,500--5,700) fewer myocardial infarctions, 1,900 (95% UI 1,600--2,200) to 3,900 (95% UI 3,400--4,400) fewer CVD deaths, and 2,700 (95% UI 2,200--3,200) to 5,600 (95% UI 4,600--6,600) fewer deaths from any cause for "low" and "high" estimates of baseline SSB intake, respectively. A 20% reduction in SSB consumption with 39% caloric compensation is projected to result in 26,200 (95% UI 21,200--30,600) to 53,800 (95% UI 43,900--62,700) fewer cases of diabetes, 4,800 (95% UI 4,200--5,300) to 10,000 (95% UI 8,800--11,200) fewer myocardial infarctions, and 5,200 (95% UI 4,300--6,200) to 11,000 (95% UI 9,100--13,100) fewer deaths ([Table 2](#pmed.1003224.t002){ref-type="table"}).

10.1371/journal.pmed.1003224.t002

###### Projected cumulative cases of diabetes, CVD events, and deaths prevented for the period 2015--2024, assuming 39% caloric compensation, under two scenarios of SSB reduction (10% and 20%) and SSB base consumption estimation (low and high estimates).

![](pmed.1003224.t002){#pmed.1003224.t002g}

  Preventable cases           Base case total number   10% reduction, *N* (%)   20% reduction, *N* (%)                                          
  --------------------------- ------------------------ ------------------------ ------------------------ -------- ----- -------- ----- -------- -----
  **Cases of diabetes**       779,900                  13,300                   1.7                      27,700   3.6   26,200   3.4   53,800   6.9
  (10,800--15,600)            (22,400--32,400)         (21,200--30,600)         (43,900--62,700)                                                
  **Myocardial infarction**   491,700                  2,500                    0.5                      5,100    1.0   4,800    1.0   10,000   2.0
  (2,200--2,800)              (4,500--5,700)           (4,200--5,300)           (8,800--11,200)                                                 
  **Stroke**                  728,800                  1,500                    0.2                      3,100    0.4   2,900    0.4   6,000    0.8
  (1,000--2,000)              (2,100--4,100)           (1,900--3,900)           (4,200--8,200)                                                  
  **CVD deaths**              640,100                  1,900                    0.3                      3,900    0.6   3,600    0.6   7,600    1.2
  (1,600--2,200)              (3,400--4,400)           (3,200--4,100)           (6,600--8,800)                                                  
  **Total deaths**            3,309,200                2,700                    0.1                      5,600    0.2   5,200    0.2   11,000   0.3
  (2,200--3,200)              (4,600--6,600)           (4,300--6,200)           (9,100--13,100)                                                 

CVD deaths: deaths due to CHD + stroke.

**Abbreviations**: CHD, coronary heart disease; CVD, cardiovascular disease; SSB, sugar-sweetened beverage or soda; UI, uncertainty interval

[Fig 1](#pmed.1003224.g001){ref-type="fig"} shows the prevented cases of myocardial infarction, stroke, and deaths by gender and age group for the 10% consumption reduction scenario in the 10-year period. The magnitude of prevented cases was highest among men and in the youngest ages modeled, and lowest in the highest ages modeled.

![Projected prevented cases as percent of MI, strokes, CVD deaths, and overall deaths by age group and gender, 2015--2024, assuming 10% reduction in SSB consumption, under two scenarios of baseline SSB consumption.\
CVD, cardiovascular disease; MI, myocardial infarction; SSB, sugar-sweetened soda.](pmed.1003224.g001){#pmed.1003224.g001}

[Table 3](#pmed.1003224.t003){ref-type="table"} presents results from 0% and 100% caloric compensation scenarios, assuming a 10% reduction in SSB consumption. When varying the degree of caloric compensation, even under the most conservative assumption of base SSB consumption (low estimate), the reduction in diabetes ranges from 5,100 (95% UI 3,000--7,100) fewer cases assuming 100% caloric compensation (0.7% relative reduction) to 18,300 (95% UI 15,000--21,200) fewer cases (2.3% relative reduction) if we assume 0% caloric compensation.

10.1371/journal.pmed.1003224.t003

###### Projected prevented cumulative cases of diabetes, CVD events, and deaths for the period 2015--2024, assuming 10% of SSB consumption reduction, under two scenarios of caloric compensation (0% and 100%) and SSB base consumption estimation (low and high estimates).

![](pmed.1003224.t003){#pmed.1003224.t003g}

  Preventable cases           Base case total number   Low base SSB consumption estimation   High base SSB consumption estimation                                          
  --------------------------- ------------------------ ------------------------------------- -------------------------------------- ------- ------ -------- ----- -------- ------
  **Cases of diabetes**       779,900                  18,300                                2.3                                    5,100   0.7    38,200   4.9   10,500   1.3
  (15,000--21,200)            (3,000--7,100)           (31,300--44,000)                      (6,200--15,000)                                                               
  **Myocardial infarction**   491,700                  3,800                                 0.8                                    250     0.1    7,800    1.6   500      0.1
  (3,400--4,100)              (200--350)               (7,000--8,700)                        (200--900)                                                                    
  **Stroke**                  728,800                  2,100                                 0.3                                    400     0.1    4,400    0.6   900      0.1
  (1,500--2,800)              (300--550)               (3,100--5,800)                        (200--1,600)                                                                  
  **CVD deaths**              640,100                  2,800                                 0.4                                    250     0.05   5,900    0.9   500      0.1
  (2,500--3,100)              (200--300)               (5,200--6,500)                        (200--900)                                                                    
  **Total deaths**            3,309,200                3,900                                 0.1                                    600     0.02   8,200    0.2   1,300    0.04
  (3,300--4,500)              (450--750)               (6,900--9,500)                        (500--2,000)                                                                  

CVD deaths: deaths due to CHD + stroke.

**Abbreviations**: CHD, coronary heart disease; CVD, cardiovascular disease; SSB, sugar-sweetened beverage or soda; UI, uncertainty interval

The decreased rate of incident diabetes cases under the 6 scenarios of taxation and caloric compensation (10% and 20% consumption reduction, 0%, 39%, and 100% caloric compensation), for low and high estimates of current SSB consumption, can be seen in [Fig 2](#pmed.1003224.g002){ref-type="fig"}. In each scenario, most of the prevented cases occur in the youngest age groups for both women and men.

![Projected prevented cases of diabetes by age group and gender for the period 2015--2024 under 6 different scenarios of SSB reduction in consumption and caloric compensation and 2 estimates of baseline SSB consumption.\
SSB, sugar-sweetened soda.](pmed.1003224.g002){#pmed.1003224.g002}

In an extreme scenario of achieving a 40% reduction of SSB consumption along with 39% caloric compensation, we estimate 49,800 (95% UI 40,400--58,200) to 101,100 (95% UI 74,200--117,300) fewer cases of diabetes, 9,500 (95% UI 8,400--10,600) to 19,700 (95% UI 16,900--22,000) fewer myocardial infarctions, and from 10,400 (95% UI 8,500--12,300) to 21,600 (95% UI 16,800--25,700) fewer deaths, respectively, for low and high estimates of baseline SSB consumption.

Discussion {#sec015}
==========

The need to reduce SSB consumption in Argentina is increasingly a matter of policy discussions in response to growing levels of obesity amidst very high levels of SSB consumption. Local evidence would best inform that debate. Using a validated computer simulation model populated with Argentine data, we found that a 10% reduction in SSB consumption among those aged 35 years and older could reduce diabetes by a magnitude of 5,100 cases (in an extremely conservative scenario) to 38,200 cases over 10 years, with a most likely impact being between 13,300 to 27,700 cases averted. These last figures would be equivalent to 1 to 2 cases of diabetes avoided for every 1,400 people over 34 years of age. Cardiovascular events and mortality could also be significantly reduced.

It is worth underscoring that, since the average daily consumption of sodas is greater among young people, most prevented cases of diabetes occur in this population. The true health benefits of SSB taxation could be higher than those we present here, as a 10-year estimate of avoided cases of CVD and death is a relatively short time period in which to perceive clinical impact among young and middle-aged adults.

A previous analysis conducted in Mexico using the CVD Policy Model-Mexico found that a 10% decrease in consumption, assuming 39% caloric compensation, could prevent almost 190,000 diabetes cases over a 10-year period, many more than the 13,300 to 27,700 cases resulting from the same scenario in Argentina. This large difference is likely due to the size of Mexico's population (almost 3 times larger than Argentina's) \[[@pmed.1003224.ref045],[@pmed.1003224.ref046]\], a higher average daily SSB consumption in the Mexico analysis (that additionally included all sugary drinks), and a current higher rate of obesity in Mexico. In 2013, Mexico implemented an excise tax on soft drinks; estimates after year 2 indicate that taxed beverages per capita sales were reduced by 7.3%, while per capita sales of plain water increased 5.2% \[[@pmed.1003224.ref018]\]. Mexico's experience informs what Argentina could foresee as expected benefits of a tax policy aimed at reducing SSB consumption.

Our study limitations are mainly related to the limited availability of SSB consumption data in Argentina. We have undertaken several strategies to obtain valid estimates given these limitations, and we present a range of assumptions. The SSB daily serving size as reported by the CESCAS I study (which provides our "low" intake estimate) is likely to be underestimating total consumption. This would bias our results toward a more conservative estimate of health benefits. We have also modeled the health benefits of a consumption reduction using an alternative, less conservative, estimate of current SSB intake in the population. Additionally, our main scenario assumes a 39% caloric compensation; this estimate comes from US data \[[@pmed.1003224.ref041]\] and may be higher or lower in Argentina or could vary in a systematic way over time. Also, the effect size and all model parameters are held constant, varying only by age as the population ages, which is both a strength and a limitation of modeling. To account for these possibilities, we have also modeled the 2 extremes cases of 0% and 100% caloric compensation. Finally, we were only able to model the possible benefits for the population older than 34 years---the age range analyzed by the CVD Policy Model---and for a 10-year period. As most sodas are consumed by younger people, the health benefits of consumption reduction could be higher among younger generations over time.

Despite uncertainty about the distribution of SSB consumption among Argentina's population, the government will need to make public health policy decisions about whether and how to limit SSB consumption. Our study finds that, even under conservative assumptions, a relatively small reduction in SSB consumption could lead to a significant decrease in diabetes incidence, CVD events, and mortality. These results support policies to increase the price of these products using taxation as a potential tool to reduce SSB consumption, which would have the additional advantage of providing a new source of public funds to support healthy lifestyles.

Argentina has previously used computer simulation research results to foster national policy development. For example, other modeling studies on tobacco control \[[@pmed.1003224.ref047]\] and salt consumption \[[@pmed.1003224.ref048]\] (using the CVD Policy Model-Argentina) highlighted the impact of potential policies that were subsequently implemented. The results of this study should contribute to the development and implementation of evidence-based policies aimed at decreasing SSB consumption in Argentina.

Supporting information {#sec016}
======================

###### The Cardiovascular Disease Policy Model.

Update and calibration of CVDPM-Argentina. SSB consumption estimations. Table A: Local data sources for CVD Policy Model-Argentina update and calibration. Table B: Comparison of overall outcomes between model predictions (CVDPM-Arg) and actual statistics in Argentina, 2010. Table C: Summary of variables used for the forecasting of the effect of SSB taxation in Argentina on diabetes, CVDs, and mortality outcomes. Table D: Daily per capita consumption of SSBs in Argentina, by age group and gender, by self-report from 2 cities, 2010--2011. Table E: Comparison of 2 different methodologies for estimating SSB per capita daily consumption in Argentina. CVD, cardiovascular disease; CVDPM-Arg, Cardiovascular Disease Policy Model-Argentina; SSB, sugar-sweetened beverage or soda.
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###### Cardiovascular disease (CVD) Policy Model structure.
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###### Directed acyclic graph describing the relationship between changes in SSB consumption and risk factors and outcomes in the CVD Policy Model-Argentina.

CVD, cardiovascular disease; SSB, sugar-sweetened beverage.
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###### Prospective protocol from funding proposal.
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###### Checklist of items that should be included in reports of observational studies.

STROBE, Strengthening the Reporting of Observational Studies in Epidemiology.
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:   body mass index
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:   coronary heart disease

CVD Policy Model-Argentina

:   Cardiovascular Disease Policy Model-Argentina

CVD

:   cardiovascular disease

ENNyS

:   Encuesta Nacional de Nutrición y Salud

PrEViSTA

:   Program for the Epidemiological Evaluation of Stroke in Tandil

SBP

:   systolic blood pressure
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:   sugar-sweetened beverage

STROBE

:   Strengthening the Reporting of Observational Studies in Epidemiology

UI

:   uncertainty interval
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Your paper was evaluated by a senior editor and discussed among all the editors here. It was also discussed with an academic editor with relevant expertise, and sent to independent reviewers, including a statistical reviewer. The reviews are appended at the bottom of this email and any accompanying reviewer attachments can be seen via the link below:

\[LINK\]

In light of these reviews, I am afraid that we will not be able to accept the manuscript for publication in the journal in its current form, but we would like to consider a revised version that addresses the reviewers\' and editors\' comments. Obviously we cannot make any decision about publication until we have seen the revised manuscript and your response, and we plan to seek re-review by one or more of the reviewers.

In revising the manuscript for further consideration, your revisions should address the specific points made by each reviewer and the editors. Please also check the guidelines for revised papers at <http://journals.plos.org/plosmedicine/s/revising-your-manuscript> for any that apply to your paper. In your rebuttal letter you should indicate your response to the reviewers\' and editors\' comments, the changes you have made in the manuscript, and include either an excerpt of the revised text or the location (eg: page and line number) where each change can be found. Please submit a clean version of the paper as the main article file; a version with changes marked should be uploaded as a marked up manuscript.

In addition, we request that you upload any figures associated with your paper as individual TIF or EPS files with 300dpi resolution at resubmission; please read our figure guidelines for more information on our requirements: <http://journals.plos.org/plosmedicine/s/figures>. While revising your submission, please upload your figure files to the PACE digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <PLOSMedicine@plos.org>.

We expect to receive your revised manuscript by Jun 05 2020 11:59PM. Please email us (<plosmedicine@plos.org>) if you have any questions or concerns.

\*\*\*Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.\*\*\*

We ask every co-author listed on the manuscript to fill in a contributing author statement, making sure to declare all competing interests. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. If new competing interests are declared later in the revision process, this may also hold up the submission. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT. You can see our competing interests policy here: <http://journals.plos.org/plosmedicine/s/competing-interests>.

Please use the following link to submit the revised manuscript:

<https://www.editorialmanager.com/pmedicine/>

Your article can be found in the \"Submissions Needing Revision\" folder.

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see <http://journals.plos.org/plosmedicine/s/submission-guidelines#loc-methods>.

Please ensure that the paper adheres to the PLOS Data Availability Policy (see <http://journals.plos.org/plosmedicine/s/data-availability>), which requires that all data underlying the study\'s findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by \"data not shown\" or \"unpublished results.\" For such statements, authors must provide supporting data or cite public sources that include it.

We look forward to receiving your revised manuscript.

Sincerely,

Emma Veitch, PhD

PLOS Medicine

On behalf of:

Adya Misra, PhD

Senior Editor

PLOS Medicine

[plosmedicine.org](http://plosmedicine.org)

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

Requests from the editors:

\*Just to note that this paper is being considered for the journal\'s special issue on Obesity - please do liaise with Adya regarding any points regarding inclusion of this article in the special issue, and bear in mind that being able to revise in line with our deadlines will help ensure inclusion, if the article passes peer review.

\*As noted by one reviewer, addressing more fully the range of parameter uncertainty in the model would be helpful, although we recognise this would represent a substantial amount of reworking of the paper and presentation of the findings. However we look forward to the authors\' justification on this point, and if the authors choose not to address this in the way suggested by the reviewer, we feel a strong justification would be needed.

\*Please structure your abstract using the PLOS Medicine headings (Background, Methods and Findings, Conclusions- \"Methods and Findings\" should be a single subsection).

\*At this stage, we ask that you include a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract. Please see our author guidelines for more information: <https://journals.plos.org/plosmedicine/s/revising-your-manuscript#loc-author-summary>

\*In the last sentence of the Abstract Methods and Findings section, please describe the main limitation(s) of the study\'s methodology.

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

Comments from the reviewers:

Reviewer \#1: This is a statistical review of manuscript PMEDICINE-D-20-00333_R1. The manuscript reads well. I do not have any specific comment on this manuscript in its current state.

However, I have an important suggestion that might improve the manuscript. In its current state, the modelling exercise does not take into account the uncertainty in the parameters of Table 1. For example, the effect on systolic blood pressure is 0.78 mmHg (95% CI 0.09 to 1.47), but the authors use 0.78 mmHg in the model, as shown on Figure S2. A more realistic modelling exercise would use Monte-Carlo simulations to assess the reduction in number of events by taking into account the uncertainty on all parameters of Table 1 (diabetes, fatal and non-fatal cvd events, mortality). Using Monte-Carlo simulations, the authors would be able to provide a range for their estimates (and present this visually using histograms) for the various scenarios (low vs high consumption, caloric compensation of 0% , 39% and 100%).

I recognise that my suggestion will generate more work for the authors. Nonetheless I think that providing uncertainty intervals for the estimates would noticeably improve the paper. For example, the sentence in the abstract that currently reads \"a 10% reduction in SSB with a caloric compensation of 39% is projected to reduce incident diabetes cases by 13300 to 27700 cases compared to a scenario of no change in SSB consumption\" would include uncertainty intervals around 13300 and 27700. Given the uncertainty in the effects of the intervention (as recognised in Table 1) it would be more appropriate to propagate the uncertainty in the modelling exercise.

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

Reviewer \#2: The CVD policy model-Argentina assessed the impact of an SSB taxation in Argentina, it models a lower and a high-consumption scenario with different levels of compensation from other beverages. The paper shows that even if with 10% reduction in soda consumption from the Argentinian population an important number of diabetes and CVD cases can be avoided. The clearly stated the assumptions of the model and limitations of the available data

This is a clear and well written paper. Obesity in Argentina is a great public health problem. I believe that the results from this paper will provide good evidence to support the implementation of a soda taxation. Results from this simulation model has been previously used for policy advocacy, in Mexico, US for SSB tax and Argentina for Salt reduction. Using Simulation Modeling for assessment of regulatory actions is becoming a very popular tool for the health research community not only for policy but also as a method to assess the epidemiological data needed for a better evaluation.

This work is likely to mater to the public health community who will translate the results to disseminate for policy makers and other Ministry of Health stakeholders. Given the implementation of SSB tax all over the world this study is of likely interest to all readers.

Minor comment.

Abstract: The line before conclusions, please clarify at which age gender you refer when saying.\" Cardiovascular events occurred in the youngest age group (35-44 y)\" It is confusing as you mentioned afterwards that the reduction would also occur in men all age.

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

Reviewer \#3:

Projected impact of a reduction in sugar-sweetened beverages consumption on diabetes and cardiovascular disease in Argentina: a modeling study\"

PLos Medicine

This is a very good simulation exercise yielding much needed estimations for Argentina about the potential impact of raising taxes on SSBs on important outcomes as CVD morbidity and mortality.

They used a very well-known Markov model developed by L. Goldman and M. Weinstein, based on those equations and risk estimations derived from the Framingham cohort study.

I would like to praise the authors for making an importan effort in identifying appropriate locally relevant parameters, about consumption and sales, caloric compensation, and relative risks for selected conditions. It is also a strength to consider low- and high- consumption, and three taxing scenarios.

They focused on CVD outcomes, due to the nature of the model they selected, which is only part of the global SSB public health picture. It is important to note that for SSBs as a health risk factor, the population of children, adolescents and young adults is the most affected and this is not adequately captured by this model. Also, other relevant public health outcomes such as dental caries, bullying, depression, cancer of many sites, and many medical conditions such as non-ischemic heart disease, osteoarthritis, kidney disease, dementia and others, could be incorporated in future SSB-specific modeling. The discussion should have highlighted this wider panorama. From the content point of view, what seems to be also missing is a clear and wider explanation of ‎strengths/weaknesses, particularly in context of other concurrent measures to be taken in NCD prevention.

Overall, the manuscript has potential to soundly modify health policy, especially if coupled with other more SSB-specific simulations. I strongly recommend this paper to be published.

Minor comments:

Ref11 is a short newspaper article, not suitable as a source for a manuscript in my opinion. Better to original sources. Euromonitor is referenced elsewhere in the manuscript.

Ref 41 for the estimate of calorie compensation is rather old.

doi: 10.1038/ijo.2015.177 This meta-analysis from Rogers et al could be helpful. However the authors correctly considered two extreme cases to account for this.

The authors assume that all cities in Argentina consume soda in the same way of Bariloche and Marcos Paz, hopefully during 2020 the second ENNyS survey will be published and more representative data is available. In the meantime, I think what they did is OK and is properly discussed.

Table 1. Some relative risks (RRs) might have been more updated or better substantiated by evidence. For example, the Global Burden of Disease 2017 study, available from <http://ghdx.healthdata.org/gbd-results-tool> would be an alternative and excellent source for deriving updated RRs

S2 table: what are exactly MI Deaths and arrests? what ICD10 codes were considered? There is no mention of corrections for garbage codes, or under-reporting of CV deaths, although it seems to have been done, and stated in the Medicina companion paper (Ref 27), I think it is worth to mention this in the main manuscript and in the Supplementary file.

BMI effects on CVD events independent of DBT and lipids are not considered, possibly making the model estimates even more conservative. See for example DOI: 10.1001/archinte.167.16.1720 This could be discussed.

Also, the model applied changes in the first year and then assumes to hold constant which could be questionable.

Other technical comments:

The term \'diabetes\' should be replaced by \'Type 2 Diabetes Mellitus\' which is more accurate.

Table 2: it wold be clearer to say CVD deaths instead of CVD mortality (which is a rate)

Fig 2 almost unreadable, need to fix the resolution of the image.

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

Any attachments provided with reviews can be seen via the following link:

\[LINK\]

10.1371/journal.pmed.1003224.r003

Author response to Decision Letter 1

4 Jun 2020

###### 

Submitted filename: Salgado et al - response to editors-reviewers.docx

###### 

Click here for additional data file.

10.1371/journal.pmed.1003224.r004
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8 Jun 2020

Dear Dr. Salgado,

Thank you very much for re-submitting your manuscript \"Projected impact of a reduction in sugar-sweetened beverages consumption on diabetes and cardiovascular disease in Argentina: a modeling study\" (PMEDICINE-D-20-00333R2) for review by PLOS Medicine.

I have discussed the paper with my colleagues and the academic editor and it was also seen again by reviewers. I am pleased to say that provided the remaining editorial and production issues are dealt with we are planning to accept the paper for publication in the journal.

The remaining issues that need to be addressed are listed at the end of this email. Any accompanying reviewer attachments can be seen via the link below. Please take these into account before resubmitting your manuscript:

\[LINK\]

Our publications team (<plosmedicine@plos.org>) will be in touch shortly about the production requirements for your paper, and the link and deadline for resubmission. DO NOT RESUBMIT BEFORE YOU\'VE RECEIVED THE PRODUCTION REQUIREMENTS.

\*\*\*Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.\*\*\*

In revising the manuscript for further consideration here, please ensure you address the specific points made by each reviewer and the editors. In your rebuttal letter you should indicate your response to the reviewers\' and editors\' comments and the changes you have made in the manuscript. Please submit a clean version of the paper as the main article file. A version with changes marked must also be uploaded as a marked up manuscript file.

Please also check the guidelines for revised papers at <http://journals.plos.org/plosmedicine/s/revising-your-manuscript> for any that apply to your paper. If you haven\'t already, we ask that you provide a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract.

We expect to receive your revised manuscript within 1 week. Please email us (<plosmedicine@plos.org>) if you have any questions or concerns.

We ask every co-author listed on the manuscript to fill in a contributing author statement. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT.

Please ensure that the paper adheres to the PLOS Data Availability Policy (see <http://journals.plos.org/plosmedicine/s/data-availability>), which requires that all data underlying the study\'s findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by \"data not shown\" or \"unpublished results.\" For such statements, authors must provide supporting data or cite public sources that include it.

If you have any questions in the meantime, please contact me or the journal staff on <plosmedicine@plos.org>.

We look forward to receiving the revised manuscript by Jun 15 2020 11:59PM.

Sincerely,

Adya Misra, PhD

Senior Editor

PLOS Medicine

[plosmedicine.org](http://plosmedicine.org)

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

Requests from Editors:

Abstract needs additional background to provide context for the study

Some tempering of language in the abstract and throughout the submission- "would" and "were" should be changed to "could", "occurred" should be changed to "observed" to reflect the study design and observational nature of your study

Please add a space between text and reference square brackets followed by a full stop throughout.

Throughout the manuscript please avoid the use of stigmatising labels such as "overweight" or "obese" and instead use "unhealthy weight" and "with obesity"

Line 111 please revise to "non-communicable" disease

Line 154, 158 "gender" should be revised to "sex"

Prospective analysis plan

Table 2,3- please add "projected" when you mention prevented as this is a modelling study. The same goes for figures and captions

Please ensure that the study is reported according to the STROBE guideline, and include the completed checklist as Supporting Information. When completing the checklist, please use section and paragraph numbers, rather than page numbers. Please add the following statement, or similar, to the Methods: \"This study is reported as per the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline (S1 Checklist).\"

Did your study have a prospective protocol or analysis plan? Please state this (either way) early in the Methods section.

a\) If a prospective analysis plan (from your funding proposal, IRB or other ethics committee submission, study protocol, or other planning document written before analyzing the data) was used in designing the study, please include the relevant prospectively written document with your revised manuscript as a Supporting Information file to be published alongside your study, and cite it in the Methods section. A legend for this file should be included at the end of your manuscript.

b\) If no such document exists, please make sure that the Methods section transparently describes when analyses were planned, and when/why any data-driven changes to analyses took place.

c\) In either case, changes in the analysis\-- including those made in response to peer review comments\-- should be identified as such in the Methods section of the paper, with rationale.

\- it looks like the model has been published previously, but I\'m not sure \"contact the authors\" in the data statement complies with our usual policy - that might be best removed

\- \"per capita\" at line 26

\- around line 40, it would be helpful to quote the projected percentage reduction in incident T2D cases, as at line 252

\- At lines 56 and 85, suggest replacing \"significant\" with \"substantial\" (or similar)

\- At line 76, \"projected to decrease\" is not quite grammatical (e.g., \"projected to lead to a decrease\")

\- \"Discussion\" at line 296

\- At line 302 where the authors summarize the findings, they start by noting a conservative projected reduction of 5100 T2D cases, which I don\'t think is quoted in the abstract or author summary (it does appear in the results). I\'d suggest they restructure this to avoid confusing readers

Comments from Reviewers:

Any attachments provided with reviews can be seen via the following link:

\[LINK\]

10.1371/journal.pmed.1003224.r005

Author response to Decision Letter 2

19 Jun 2020

###### 

Submitted filename: Salgado et al - response to editor.docx

###### 

Click here for additional data file.

10.1371/journal.pmed.1003224.r006
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22 Jun 2020

Dear Dr. Salgado,

On behalf of my colleagues and the academic editor, Dr. Sanjay Basu, I am delighted to inform you that your manuscript entitled \"Projected impact of a reduction in sugar-sweetened beverages consumption on diabetes and cardiovascular disease in Argentina: a modeling study\" (PMEDICINE-D-20-00333R3) has been accepted for publication in PLOS Medicine.

PRODUCTION PROCESS

Before publication you will see the copyedited word document (in around 1-2 weeks from now) and a PDF galley proof shortly after that. The copyeditor will be in touch shortly before sending you the copyedited Word document. We will make some revisions at the copyediting stage to conform to our general style, and for clarification. When you receive this version you should check and revise it very carefully, including figures, tables, references, and supporting information, because corrections at the next stage (proofs) will be strictly limited to (1) errors in author names or affiliations, (2) errors of scientific fact that would cause misunderstandings to readers, and (3) printer\'s (introduced) errors.

If you are likely to be away when either this document or the proof is sent, please ensure we have contact information of a second person, as we will need you to respond quickly at each point.

PRESS

A selection of our articles each week are press released by the journal. You will be contacted nearer the time if we are press releasing your article in order to approve the content and check the contact information for journalists is correct. If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact.

PROFILE INFORMATION

Now that your manuscript has been accepted, please log into EM and update your profile. Go to <https://www.editorialmanager.com/pmedicine>, log in, and click on the \"Update My Information\" link at the top of the page. Please update your user information to ensure an efficient production and billing process.

Thank you again for submitting the manuscript to PLOS Medicine. We look forward to publishing it.

Best wishes,

Adya Misra, PhD

Senior Editor

PLOS Medicine

[plosmedicine.org](http://plosmedicine.org)

[^1]: The authors have declared that no competing interests exist.
